Logo
x

Search

Subscribe Now

Gastric Cancers

Insights+ Key Biosimilars Events of May 2019

Insights+ Key Biosimilars Events of May 2019

  • June 4, 2019
Biocon and Mylan's Ogivri (trastuzumab- biosimilar) Receives Health Canada's Approval for HER2-Positive Breast and Gastric Cancers

Biocon and Mylan's Ogivri (trastuzumab- biosimilar) Receives Health Canada's Approval for HER2-Positive Breast and Gastric Cancers

  • May 22, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.